Good to see. Adjusting to reflect the lower profit-per-share forecasts due to dilution, which will take some of the pressure off the weak Bio A sales result.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%